89 Views | 26 Downloads
CB is the Principal Investigator of this study. CB, PS, THH, MCT, ALW, MRD, ACH, TC, AV, PS, SHHM, RV, and SDB collaborated in the design and oversight of the overall study. TC, AV, SHHM led trainings study team members and oversee data collection. BWW and CD conducted analyses and wrote the initial drafts of this manuscript. All authors reviewed the manuscript, and all take responsibility for its integrity as well as the accuracy of the analysis.
This study is a collaborative effort between Johns Hopkins Bloomberg School of Public Health, U.S. CDC Division of HIV/AIDS Prevention (DHAP), the Thailand Ministry of Public Health, Mahidol University, APCOM, and the community-based organizations RSAT and SWING. This work would not have been possible without the hard work and contributions of the COPE Study Team. We also thank Gilead Sciences for their generous donation of the study drug, Truvada®.
Research reported in this publication is supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the US National Institutes of Health (NIH) under Award Number R01AI118505 (PI: Beyrer) and direct funding support from CDC/DHAP. This research has been facilitated by the infrastructure and resources provided by the Johns Hopkins University Center for AIDS Research, an NIH funded program (P30AI094189), which is supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, NIGMS, NIDDK, and OAR.
The study drug, Truvada®, was donated to the project by Gilead Sciences. Gilead Sciences were provided the opportunity to provide comments on the manuscript but had no role in the interpretation of study results. Andrea Wirtz and Chris Beyrer also received separate research funding support from Gilead Sciences and ViiV Healthcare. All other authors declare no conflicts of interest.